Hostname: page-component-848d4c4894-8kt4b Total loading time: 0 Render date: 2024-06-16T20:55:00.575Z Has data issue: false hasContentIssue false
  • English
  • Français

Two Causes of Demyelinating Neuropathy in One Patient: CMT1A and POEMS Syndrome

Published online by Cambridge University Press:  02 December 2014

Nizar Chahin ,
Steven R. Zeldenrust ,
Kimberly K. Amrami ,
JaNean K. Engelstad ,
P. James  and
B. Dyck
Nizar Chahin
Affiliation:
Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Steven R. Zeldenrust
Affiliation:
Department of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Kimberly K. Amrami
Affiliation:
Department of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
JaNean K. Engelstad
Affiliation:
Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
P. James
Affiliation:
Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
B. Dyck
Affiliation:
Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Peer Reviewed Letter
Information
Canadian Journal of Neurological Sciences , Volume 34 , Issue 3 , August 2007 , pp. 380 - 385
Copyright
Copyright © The Canadian Journal of Neurological 2007

References

1. Birouk, N, Gouider, R, Le Guern, E, Gugenheim, M, Tardieu, S, Maisonobe, T, et al. Charcot-Marie-Tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. Brain. 1997;120(Pt 5):813–23.CrossRefGoogle ScholarPubMed
2. Dyck, PJ, Dyck, PJB, Chalk, CH. The 10 P’s: A mnemonic helpful in characterization and differential diagnosis of peripheral neuropathy. Neurology. 1992;42:14–8.CrossRefGoogle Scholar
3. Dispenzieri, A, Kyle, RA, Lacy, MQ, Rajkumar, SV, Therneau, TM, Larson, DR, et al. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101(7):2496–506.CrossRefGoogle ScholarPubMed
4. Dispenzieri, A. POEMS Syndrome. Hematology (Am Soc Hematol Educ Program). 2005:360–7.CrossRefGoogle ScholarPubMed
5. Dyck, PJ, Sherman, WR, Hallcher, LM, Service, FJ, O’Brien, PC, Grina, LA, et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol. 1980;8(6):590–6.CrossRefGoogle ScholarPubMed
6. Lupski, JR, de Oca-Luna, RM, Slaugenhaupt, S, Pentao, L, Guzzetta, V, Trask, BJ, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell. 1991;66:219–32.CrossRefGoogle ScholarPubMed
7. Dyck, PJ, Swanson, CJ, Low, PA, Bartleson, JD, Lambert, EH. Prednisone-responsive hereditary motor and sensory neuropathy. Mayo Clin Proc. 1982;57:239–46.Google Scholar
8. Murakami, T, Oomori, H, Hara, A, Uyama, E, Mita, S, Uchino, M. Atypical phenotype of charcot-marie-tooth disease type 1A. Muscle Nerve. 1999;22(11):1593–6.3.0.CO;2-H>CrossRefGoogle ScholarPubMed
9. Malandrini, A, Villanova, M, Dotti, MT, Federico, A. Acute inflammatory neuropathy in Charcot-Marie-Tooth disease. Neurology. 1999;52(4):859–61.Google Scholar
10. Gabriel, CM, Gregson, NA, Wood, NW, Hughes, RA. Immunological study of hereditary motor and sensory neuropathy type 1a (HMSN1a). J Neurol Neurosurg Psychiatry. 2002;72(2):230–5.Google Scholar
11. Vital, A, Vital, C, Lagueny, A, Ferrer, X, Ribiere-Bachelier, C, Latour, P, et al. Inflammatory demyelination in a patient with CMT1A. Muscle Nerve. 2003;28(3):373–6.CrossRefGoogle Scholar
12. Ginsberg, L, Malik, O, Kenton, AR, Sharp, D, Muddle, JR, Davis, MB, et al. Coexistent hereditary and inflammatory neuropathy. Brain. 2004;127(Pt 1):193–202.CrossRefGoogle ScholarPubMed
13. Carvalho, AA, Vital, A, Ferrer, X, Latour, P, Lagueny, A, Brechenmacher, C, et al. Charcot-Marie-Tooth disease type 1A: clinicopathological correlations in 24 patients. J Peripher Nerv Syst. 2005;10(1):85–92.CrossRefGoogle ScholarPubMed
14. Castleman, B, Towne, VW. Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N Engl J Med. 1954;251(10):396–400.Google Scholar
15. Castleman, B, Iverson, L, Menendez, VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9(4):822–30.Google Scholar
16. Dispenzieri, A, Gertz, MA. Treatment of Castleman’s disease. Curr Treat Options Oncol. 2005;6(3):255–66.Google Scholar
17. Keller, AR, Hochholzer, L, Castleman, B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29(3):670–83.Google Scholar
18. Mallory, A, Spink, WW. Angiomatous lymphoid hamartoma in the retroperitoneum presenting with neurologic signs in the legs. Ann Intern Med. 1968;69(2):305–8.Google Scholar
19. Donaghy, M, Hall, P, Gawler, J, Gregson, NA, Leibowitz, S, Jitpimolmard, S, et al. Peripheral neuropathy associated with Castleman’s disease. J Neurol Sci. 1989;89(2-3):253–67.CrossRefGoogle ScholarPubMed
20. Watanabe, O, Arimura, K, Kitajima, I, Osame, M, Maruyama, I. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet. 1996;347:702.CrossRefGoogle ScholarPubMed
21. Soubrier, M, Dubost, JJ, Serre, AF, Ristori, JM, Sauvezie, B, Cathebras, P, et al. Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor. Arthritis Rheum. 1997;40(4):786–7.Google Scholar
22. Watanabe, O, Maruyama, I, Arimura, K, Kitajima, I, Arimura, H, Hanatani, M, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve. 1998;21(11):1390–7.Google Scholar
23. Dyck, PJ, Engelstad, J, Dispenzieri, A. Vascular endothelial growth factor and POEMS. Neurology. 2006;66(1):10–2.Google Scholar
24. Nishi, J, Arimura, K, Utsunomiya, A, Yonezawa, S, Kawakami, K, Maeno, N, et al. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman’s disease. Br J Haematol. 1999;104(3):482–5.CrossRefGoogle ScholarPubMed
25. Nishi, J, Maruyama, I. Increased expression of vascular endothelial growth factor (VEGF) in Castleman’s disease: proposed pathomechanism of vascular proliferation in the affected lymph node. Leuk Lymphoma. 2000;38(3-4):387–94.Google Scholar
26. Scarlato, M, Previtali, SC, Carpo, M, Pareyson, D, Briani, C, Del Bo, R, et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain. 2005;128:1911–20.CrossRefGoogle ScholarPubMed
27. Jaccard, A, Royer, B, Bordessoule, D, Brouet, JC, Fermand, JP. High-dose therapy and autologous blood stem cell transplantation in POEMS syndrome. Blood. 2002;99(8):3057–9.CrossRefGoogle ScholarPubMed
28. Dispenzieri, A, Moreno-Aspitia, A, Suarez, GA, Lacy, MQ, Colon-Otero, G, Tefferi, A, et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood. 2004;104(10):3400–7.CrossRefGoogle Scholar
29. Dispenzieri, A, Gertz, MA. Treatment options for POEMS syndrome. Expert Opin Pharmacother. 2005;6(6):945–53.Google Scholar
30. Kuwabara, S, Misawa, S, Kanai, K, Kikkawa, Y, Nishimura, M, Nakaseko, C, et al. Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology. 2006;66(1):105–7.Google Scholar
31. Straume, O, Bergheim, J, Ernst, P. Bevacizumab therapy for POEMS syndrome. Blood. 2006;107(12):4972–3; author reply 3-4.Google Scholar